Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers.

ABSTRACT: The advent of immune checkpoint therapy for metastatic skin cancer has greatly improved patient survival. However, most skin cancer patients are refractory to checkpoint therapy, and furthermore, the intra-immune cell signaling driving response to checkpoint therapy remains uncharacterized. When comparing the immune transcriptome in the tumor microenvironment of melanoma and basal cell carcinoma (BCC), we found that the presence of memory B cells and macrophages negatively correlate in both cancers when stratifying patients by their response, with memory B cells more present in responders. Moreover, inhibitory immune signaling mostly decreases in melanoma responders and increases in BCC responders. We further explored the relationships between macrophages, B cells and response to checkpoin

SUBMITTER: Dollinger E 

PROVIDER: S-EPMC7599806 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature